Corbus Pharmaceuticals Holdings (CRBP) Accounts Payables (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Accounts Payables of $2.2 million for Q4 2025, down 53.72% year-over-year from $4.8 million in Q4 2024, and down 19.16% quarter-over-quarter from $2.7 million in Q3 2025.
Corbus Pharmaceuticals Holdings (CRBP) Accounts Payables (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Accounts Payables history runs 13 years deep, the most recent figure standing at $2.2 million for Q4 2025.
- In Q4 2025, Accounts Payables fell 53.72% year-over-year to $2.2 million; the TTM figure through Dec 2025 stood at $2.2 million (down 53.72% YoY), while the FY2025 annual figure was $2.2 million, down 53.72% from the prior year.
- Accounts Payables for Q4 2025 stood at $2.2 million, down from $2.7 million in the prior quarter.
- The five-year high for Accounts Payables was $4.8 million in Q4 2024, with the low at $1.2 million in Q2 2024.
- The 5-year median for Accounts Payables is $2.4 million (2021), against an average of $2.6 million.
- The sharpest annual moves came in 2021 and 2025: Accounts Payables slumped 85.21% in 2021, then jumped 246.18% in 2025.
- Corbus Pharmaceuticals Holdings' Accounts Payables stood at $1.8 million in 2021, then increased by 21.98% to $2.2 million in 2022, then jumped by 46.23% to $3.2 million in 2023, then soared by 50.55% to $4.8 million in 2024, then slumped by 53.72% to $2.2 million in 2025.
- Business Quant data shows CRBP's Accounts Payables at $2.2 million in Q4 2025, $2.7 million in Q3 2025, and $4.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - | 2.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.22 Mn |
| Sep 30, 2025 | 2.74 Mn |
| Jun 30, 2025 | 3.99 Mn |
| Mar 31, 2025 | 4.07 Mn |
| Dec 31, 2024 | 4.79 Mn |
| Sep 30, 2024 | 2.89 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 2.08 Mn |
| Dec 31, 2023 | 3.18 Mn |
| Sep 30, 2023 | 4.71 Mn |
| Jun 30, 2023 | 1.51 Mn |
| Mar 31, 2023 | 1.32 Mn |
| Dec 31, 2022 | 2.17 Mn |
| Sep 30, 2022 | 1.37 Mn |
| Jun 30, 2022 | 1.99 Mn |
| Mar 31, 2022 | 2.70 Mn |
| Dec 31, 2021 | 1.78 Mn |
| Sep 30, 2021 | 2.55 Mn |
| Jun 30, 2021 | 1.88 Mn |
| Mar 31, 2021 | 3.62 Mn |